Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Shionogi Shifts Sales Focus To Crestor

This article was originally published in PharmAsia News

Executive Summary

Japan's Shionogi plans to step up its promotions in hospitals to create an 83 percent increase in domestic sales of its Crestor (rosuvastatin) cholesterol drug by next March. The company said it would train some of its 1,450 medical representatives to promote use of the drug in hospitals instead of only to clinics, and to track the frequency with which it is prescribed. The focus on the statin marks a shift by Shionogi away from anti-microbial agents and their declining sales to metabolic syndrome medicines. (Click here for more - a subscription may be required

You may also be interested in...

Shionogi Expects Crestor To Overtake Pfizer’s Lipitor

TOKYO - Shionogi & Co. of Osaka is projecting domestic sales of its cholesterol treatment Crestor (rosuvastatin) to grow 82 percent in fiscal 2008 to ¥19 billion ($180 million), thanks to its lower price and additional efficacy compared to competitor Pfizer's Lipitor (atorvastatin), a company official said July 2

Ahead Of Ryoncil’s Advisory Committee, Citizen Petition Opposes Approval For Pediatric GVHD

Lawyer asks US FDA to require another trial before licensing Mesoblast’s stem cell therapy for children with SR-aGVHD; Incyte’s Jakafi is only product approved for the indication.

Merck Picks Up Hanmi’s Dual Agonist Efinopegdutide, But For NASH

Hanmi licenses out GLP-1/glucagon receptor dual agonist for NASH to Merck, in a deal worth up to $870m, marking a positive turn for the Korean firm's pipeline after Janssen returned rights last year.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts